

Life Settlement Assets PLC – Ordinary Share A

Investment Objective

The company's investment objective is to achieve capital appreciation by purchasing policies or portfolios of life settlement and mortality-related products in special or distressed situations.

Commentary

The Company's external actuary's valuation as of December 2018 has now been received. The actuary performed a nine-year A/E study based on historical data available and made some improvements to the mortality assumptions. The HIV and non-HIV segments have been set at a long-term A/E ratio of 100% or above. The retained valuation stands at about \$41M for the HIV policies at an 11% discount rate and around \$24M for the Non-HIV at a 12% discount rate. For 2018 alone, the A/E ratio is above 100% for the HIV segment, and slightly above 80% for the Non-HIV segment. The market A/E is reported to be around 65%-70%. While there is no firm number, the discount rate used by the market is reported to be on a downwards trend, possibly reflecting lower risks associated with the use of more conservative medical underwriting.

The Share Class is reporting a positive performance of 4.64% for the month of December. Five maturities for a total death benefit of \$ 0.4M were registered in the HIV segment; five maturities were registered in the non-HIV segment, for a total coverage of \$ 8.6M. One of the insureds was the most valuable policy on the Top 3 exposure list of the Share Class. It had a face of \$8.1M. In addition, a small portfolio of fractionals, to which the trust was overwhelmingly already exposed to, was added in order to prevent any undue lapsing.


Investment Terms	Estimated NAV (USD)	NAV/Share
1.5% Management Fee	91,654,216.31	2.0167

Number Of Policies	Death Benefits (USD)	Matured Policies YTD*	Maturities YTD (USD)*
4 626	463 626 606	115	21 497 398


Trust Investment Manager	Acheron Capital Ltd.	Company Secretary	Maitland Administration Services Limited
Administrator	Compagnie Européenne de Révision	ISIN	GB00BF1Q4B05
		Ticker	LSAA
Auditor	Grant Thornton UK LLP	Info	life@acheroncapital.com +44 207 258 5990

*This figure refers to maturities occurred in the portfolio held by Acheron Portfolio Trust


Distribution by Age




Distribution by Death Benefit Amount⁽¹⁾ (USD)




Distribution By Gender




Distribution by Insurance Company



Distribution by Issue Date⁽²⁾ (Yrs)



Maturities Since Inception




(1)Indicates the available face amount to LSA which is a fractional interest of initial face amount.

(2)Distribution by issue dates reflects the time since the life insurance policy was issued.

Source of Data: Acheron Capital Ltd unless otherwise stated.


Historical Maturity



Maturities December 2018

Number of policies matured in December 2018	10
Corresponding number of insured	6
Total death benefit in December 2018(US\$)	9 077 268
Valuation of Matured policies in Book (US\$)	4 384 432

Notification of Maturity



Premiums Situation (US\$) ⁽¹⁾

Servicers Premiums Projection as of Beginning 2018	\$ 13.4M
Mortality Adjusted Premiums Projection Beginning 2018	\$ 12.1M
Estimated COI Net of Mortality Beginning 2018	\$ 11.2M

Top 10 Coverage

Insured	Face (millions)	Total Face (millions)	Age (ALB)	Expiration Age*
1	8.6/2.4/1.0	12.0	99	101/121/101
2	10.2	10.2	98	100
3	3.8	3.8	93	100
4	1.9/1.4	3.3	95	100/100
5	2.8	2.8	78	100
6	1.2/0.9/0.6	2.7	76	121/100/100
7	1.2/0.8/0.4/0.1/0.1/0.1	2.7	90	100/100/100/95/100/115
8	2.7	2.7	93	100
9	1.3/1.0	2.3	94	100/115
10	2.0	2.0	91	100

Cash Situation (US\$) ⁽¹⁾

Cash at hand and similar	\$ 7.3M
Gross Cash in Policies ⁽²⁾ (estimated as of end 2017)	\$ 41.7M
Loan on Cash in Policies (estimated as of end 2017)	\$ 22.2M
Net Cash in Policies ⁽²⁾ (estimated as of end 2017)	\$ 19.5M
Maturities to be received	\$ 10.5M

(1) Figures as provided by third parties

(2) Cash in a policy can typically be borrowed at an interest rate of 4% to 8%. Cash for fractional policies and ABC policies not included. Surrender charge included. *In case that one insured has more than one policy, their expiration ages are ordered by decreasing face.

Issued by Acheron Capital Limited, a company registered in England, no. 05588630 at Suite1, 3rd Floor, 11-12 St. James's Square, London SW1Y 4LB, England.

Acheron Capital Limited is authorized and regulated by the Financial Conduct Authority ("FCA") and appears on the FS Register under FRN 443685.

The investment products and services of Acheron Capital Limited are only available to professional clients and eligible counterparties; they are not available to retail clients. This document does not constitute an offer to buy or sell shares or units in any fund or funds managed or advised by Acheron Capital Limited. The prospectus of the funds is the only authorized document for offering shares or units in the funds. The prospectus may only be distributed in accordance with the laws and regulations of each appropriate jurisdiction in which any potential investor resides. Investors are also reminded that past performance should not be seen as an indication of future performance and that they may not get back the amount originally invested. UK Investors do not benefit from the Financial Services Compensation Scheme (FSCS). Investment in the funds carry risks which are more fully described in the prospectus. The funds are only suitable for sophisticated investors who are aware of the risks of investing in hedge funds.